Since April, the Nifty Pharma index has outperformed the market by surging 15 per cent, against 1.7 per cent gain in the Nifty50 index
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
Union minister Nitin Gadkari has called up Sun Pharma's chief to arrange for 10,000 injections of Remdesivir in Nagpur in view of a shortage of the medicine here in Maharashtra
Strong US portfolio, margin gains and India business growth to support stock
The recent price chart displays a 'Bullish Flag' breakout in Happiest Minds' stock
IndusInd Bank, Kotak Mahindra Bank, ICICI Bank, Sun Pharma, Bajaj Finance, and UltraTech Cement were prominent gainers
Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma and Jubilant Pharma are recalling products in the US market, the world's largest market for pharmaceutical products, for various reasons
Key chronic segments have helped the JB Chemicals outperform the Indian pharma market.
The firm said it plans to introduce a complete range of anti-epilepsy drug Brivaracetam in the country at an affordable price
Markets regulator Sebi on Thursday allowed Thomas Cook (India) to withdraw its buyback offer because of substantial deterioration in the company's financial position
The stock price has witnessed running correction of 10 per cent from the recent high
Two whistle blowers had alleged that Sun Pharma and its subsidiary Sun Pharmaceutical Laboratories diverted funds through its sole distributor in India Aditya Medisales
Respiratory segment and anti-infectives contract; Cardiac, anti-diabetic growth rates plummet
At 12:57 pm, Nifty Pharma index, the top gainer among sectoral indices, was up 4.2 per cent, as compared to 1.3 per cent gain in the benchmark Nifty50 index
The company has repaid debt of about $490 million in 9MFY21; filings for 90 ANDAs await US FDA approval
Analysts had expected the revenues to grow around 6 per cent YoY and Ebitda margins expected to improve 42 bps YoY to 23 per cent
Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities
The board of directors of Sun Pharma are scheduled to meet on January 29, 2021 to consider and approve Q3 results
Sun Pharmaceutical Industries hit afresh 52-week high of Rs 568.50, up nearly 4 per cent in the intra-day trade today. It has surged 11 per cent in the past four trading days on the BSE
In the past three months, Sun Pharma underperformed the market by falling 1 per cent as compared to a 13 per cent rise in the S&P BSE Sensex till Friday